# EDGAR Filing Document

**Accession Number:** 0001075880
**File Stem:** 0001193125-23-048812
**Filing Date:** 2023-2
**Character Count:** 7407
**Document Hash:** 9ae3fb2e4856de72e2f60bd129a1c776
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-048812.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001193125-23-048812

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230224

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KAZIA THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001075880
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-29962
- **FILM NUMBER:** 23667889

**BUSINESS ADDRESS:**
- **STREET 1:** THREE INTERNATIONAL TOWERS LEVEL 24,
- **STREET 2:** 300 BARANGAROO AVENUE
- **CITY:** SYDNEY NSW
- **STATE:** C3
- **ZIP:** 2000
- **BUSINESS PHONE:** 01161298780088

**MAIL ADDRESS:**
- **STREET 1:** THREE INTERNATIONAL TOWERS LEVEL 24,
- **STREET 2:** 300 BARANGAROO AVENUE
- **CITY:** SYDNEY NSW
- **STATE:** C3
- **ZIP:** 2000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NOVOGEN LTD
- **DATE OF NAME CHANGE:** 19981228

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**Form 6-K** 

------

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of February, 2023** 

**Commission File Number 000-29962** 

------

## Kazia Therapeutics Limited
**(Translation of registrant's name into English)** 

------

**Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000** 

**(Address of principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT** 

On February 24, 2023, Kazia Therapeutics Limited (the "Company") issued an ASX release titled "Results of EGM" in connection with its Extraordinary General Meeting that was held on February 24, 2023 at 3:00 p.m. (Sydney time).

The Company hereby incorporates by reference the information contained herein into the Company's registration statement on Form F-3 (File No. 333-259224).

**<u>EXHIBIT LIST</u>**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [ASX Release of Kazia Therapeutics Limited dated February 24, 2023 (Extraordinary General Meeting Results)](d444919dex991.htm) |

---

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| |
|:---|
|  **Kazia Therapeutics Limited** (Registrant) |
| /s/ Karen Krumeich |
|  Karen Krumeich |
|  Chief Financial Officer |
|  Date: February 24, 2023 |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g444919dsp3a.jpg)

ASX ANNOUNCEMENT

24 February 2023

**RESULTS OF EGM** 

**Sydney, 24 February 2023** – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the results of the EGM held today at 3pm in the Company's offices. All resolutions were carried, and the results are attached.

**ENDS** 

**About Kazia Therapeutics Limited** 

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data.

Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively.

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.

For more information, please visit <u>www.kaziatherapeutics.com</u> or follow us on Twitter @KaziaTx.

------

**Kazia Therapeutics Limited** 

**Extraordinary General Meeting** 

**Friday, 24 February 2023** 

**Results of Meeting** 

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Resolution details** | **Resolution details** | **Instructions given to validly appointed proxies**<br>**(as at proxy close)** | **Instructions given to validly appointed proxies**<br>**(as at proxy close)** | **Instructions given to validly appointed proxies**<br>**(as at proxy close)** | **Instructions given to validly appointed proxies**<br>**(as at proxy close)** | **Number of votes cast on the poll<br>(where applicable)** | **Number of votes cast on the poll<br>(where applicable)** | **Number of votes cast on the poll<br>(where applicable)** | **Resolution<br>Result** |
| **Resolution** | **Resolution<br>Type** | **For** | **Against** | **Proxy's<br>Discretion** | **Abstain** | **For** | **Against** | **Abstain\*** | **Carried /<br>Not Carried** |
| 1. Ratification of Prior Issue of Atm Shares under Listing Rule 7.1A | Ordinary | 40,046,080<br> 81.66% | 8,761,171<br> 17.86% | 236,149<br> 0.48% | 143981 | 40,987,091<br> 82.39% | 8,761,171<br> 17.61% | 143981 | Carried |
| 2. Ratification of Prior Issue of Tranche 1 Placement Shares under listing rule 7.1 | Ordinary | 18,447,640<br> 73.14% | 6,537,485<br> 25.92% | 236,149<br> 0.94% | 23966107 | 19,388,651<br> 74.78% | 6,537,485<br> 25.22% | 23966107 | Carried |
| 3. Ratification of Prior Issue of Tranche 1 Placement Shares under listing rule 7.1A | Ordinary | 18,372,387<br> 72.84% | 6,582,128<br> 26.10% | 266,149<br> 1.06% | 23966717 | 19,343,398<br> 74.61% | 6,582,128<br> 25.39% | 23966717 | Carried |
| 4. Approval to Issue Tranche 2 Placement Shares under listing rule 7.1 | Ordinary | 18,256,856<br> 72.52% | 6,681,148<br> 26.54% | 236,149<br> 0.94% | 24013228 | 19,197,867<br> 74.18% | 6,681,148<br> 25.82% | 24013228 | Carried |

---

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.